Chantal Sauvageau completed her Doctorate in Medicine at Laval University in 1999, and obtained a Master’s degree in Community Health from the same University in 2002. She then completed her specialty training and obtained her certificate of specialist in Community Health from the Collège des médecins du Québec and the Royal College of Physicians and Surgeons of Canada, in 2004. She is a consultant in infectious diseases at the National Institute of Public Health of Quebec, and the Regional Directorate of Public Health of the national capital. She is a researcher in the Immunization Research Team of the Research Centre of the CHU de Québec, and an Associate Professor in the Faculty of Medicine at Laval University. She has been an active member of the Committee on Immunization of Quebec (CIQ) since 2008. She is also a member of the shingles working group as well as of the HPV working group of the National Advisory Committee on Immunization (NACI). In 2013, she participated in the work of the World Health Organization (WHO), leading to a WHO recommendation on the use of a 2-dose vaccination schedule for HPV vaccine.
Evaluate the impact of HPV vaccination and the vaccination against chickenpox and shingles
Her main research papers focus on HPV vaccination, particularly on the evaluation of the immunogenicity and efficacy of available vaccines, on the impact of varicella and shingles vaccination, on the training of healthcare professionals on immunization, and the problem of vaccine delays. More specifically, by conducting clinical trials, her projects aim to know the immune response to vaccines: duration of protection, decrease in antibody levels, impact of interactions and co-administration of vaccines on the immune response, effect of a booster dose, etc. Among other things, she is the co-principal investigator of a randomized clinical trial named ICI-HPV, having recruited 3,300 14-16 year old girls from 2013 to 2016, who are followed for 5 years. The trial aims to evaluate the effectiveness of a 2-dose schedule of HPV vaccination, 10 years after receiving the first dose of vaccine at an age of 9 or 10.
She also collaborates on projects related to the modeling and analysis of the cost-effectiveness of planned or implemented vaccination programs, as well as on studies related to the acceptability of implemented vaccination programs, by measuring the immunization coverage rate, as well as the perception of health professionals and of the population.
Canada G1E 7G9
- Fortin, PatrickMaster studentCHUL+1 418-525-4444, extension 42296
2705, boulevard Laurier
Canada G1V 4G2
- Ionescu, Iulia GabrielaMaster firstname.lastname@example.org
- Landry, Jean MichelEmployeejeanemail@example.com
- Razafimandimby, HarimahefaMaster firstname.lastname@example.org
- Verret, PhilipMaster email@example.com
Self-reported Human Papillomavirus Vaccination and Vaccine Effectiveness Among Men Who Have Sex with Men: A Quantitative Bias AnalysisJournal Article
Epidemiology, 34 (2), 2023.
Vaccine effectiveness against 12-month incident and persistent anal human papillomavirus infection among gay, bisexual, and other men who have sex with menJournal Article
J Infect Dis, 2023.
BNT162b2 effectiveness against Delta and Omicron variants of SARS-CoV-2 in adolescents aged 12-17 years, by dosing interval and durationJournal Article
J Infect Dis, 2023.
Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control studyJournal Article
Lancet Infect Dis, 23 (1), 2023.
Estimated Protection of Prior SARS-CoV-2 Infection Against Reinfection With the Omicron Variant Among Messenger RNA-Vaccinated and Nonvaccinated Individuals in Quebec, CanadaJournal Article
JAMA Netw Open, 5 (10), 2022.
Time trends in social contacts before and during the COVID-19 pandemic: the CONNECT studyJournal Article
BMC Public Health, 22 (1), 2022.
Time trends in social contacts of individuals according to comorbidity and vaccination status, before and during the COVID-19 pandemicJournal Article
BMC Med, 20 (1), 2022.
Fardeau de la varicelle et du zona à la suite de l’introduction du programme de vaccination contre la varicelle à une puis à deux doses au QuébecBook
Institut national de santé publique du Québec, Québec, QC, 2022, ISBN: 9782550914303.
COVID-19 : Transmission extérieureBook
Institut national de santé publique du Québec, Québec, QC, 2022.
Increases in human papillomavirus vaccine coverage over 12 months among a community-recruited cohort of gay, bisexual, and other men who have sex with men in CanadaJournal Article
Vaccine, 40 (26), 2022.
- Durée de l'efficacité d'un calendrier de vaccination à deux doses contre les VPH et la plus-value d'une dose de rappel : diffusion des résultats clés de l'étude ICI-VPH pour soutenir la prise de décision, from 2022-02-02 to 2024-03-30
Recently finished projects
- Évaluation de l'efficacité du programme québécois de vaccination contre le VPH : Étude de prévalence des types de VPH au Québec chez les garçons de 17 à 20 ans, from 2021-03-09 to 2022-05-31
- ICI-VPH: IMpact des calendriers d'immunisation contre les VPH, from 2013-05-01 to 2021-03-31